U-CHAMP: Urban Calgary Cardiovascular Health Assessment and Management Program - Full Text View

Sponsors and Collaborators:	University of Calgary Heart and Stroke Foundation of Ontario
Information provided by:	University of Calgary
ClinicalTrials.gov Identifier:	NCT00626041

Purpose

High blood pressure, elevated blood glucose and high cholesterol are related to the increased risk of stroke and heart disease. Many studies have shown that this risk can be significantly reduced by lowering blood pressure, blood glucose and cholesterol levels.

Through a collaborative effort between Calgary Safeway and Co-op pharmacists, the Calgary Health Region family physicians, and the Calgary Health Region Chronic Disease Management Program, U-CHAMP will deliver a program to assist in the identification and management of people with high blood pressure and through this effort, reduce the risk of heart disease and stroke in the urban Calgary population aged 18-80 years.

Condition	Intervention
Cardiovascular Diseases Hypertension Hyperlipidemia	Other: participant referral to primary care network physician

MedlinePlus related topics: Cholesterol High Blood Pressure

Drug Information available for: Cholest-5-en-3-ol (3beta)-

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Screening, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	U-CHAMP: Urban Calgary Cardiovascular Health Assessment and Management Program

Further study details as provided by University of Calgary:

Primary Outcome Measures:

Change in systolic blood pressure between baseline (average of visits one and two) and program end (final visit). [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Proportion of screened participants identified as being above blood pressure, cholesterol and blood glucose targets at visit two [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Proportion of participants that achieve published blood pressure (lipid and diabetes when appropriate) targets by program end [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Proportion of individuals that obtain both a baseline and end of program full lipid panel [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Change in British Hypertension Society global cardiovascular risk score (in those participants that do not have known vascular disease or diabetes and have a recorded baseline and end-of-study full lipid panel). [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Proportion of individuals that have changes in drug therapy (new medication and/or dosage increase). [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	110
Study Start Date:	February 2008
Estimated Study Completion Date:	June 2009
Estimated Primary Completion Date:	April 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1 referral to primary care network for management of blood pressure, lipids and diabetes.	Other: participant referral to primary care network physician blood pressure, cholesterol and hemoglobin A1c screening and management

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Adults 18-80 years
Signed consent

Exclusion Criteria:

None

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00626041

Contacts

Contact: Donna Galvin, Bsc

403 938-1589

dgalvin@platinum.ca

Locations

Canada, Alberta
Calgary Co-op Pharmacy - Crowfoot Location	Recruiting
Calgary, Alberta, Canada, T3G 2L4
Principal Investigator: Charlotte A Jones, PhD MD
Canada Safeway Pharmacy - Crowfoot Location	Recruiting
Calgary, Alberta, Canada, T3G 2L5
Principal Investigator: Charlotte A Jones, PhD MD

Sponsors and Collaborators

University of Calgary

Heart and Stroke Foundation of Ontario

Investigators

Principal Investigator:

Charlotte - Jones, PhD, MD

University of Calgary

More Information

Related Info This link exits the ClinicalTrials.gov site

Publications:

McLean DL, McAlister FA, Johnson JA, King KM, Jones CA, Tsuyuki RT. SCRIP-Hypertension program - Improving blood pressure management in patients with diabetes: The design of the SCRIP-HTN study. Canadian Pharmaceutical Journal 139: 1-4, 2006.

British Cardiac Society, British Hypertenion Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 (5): 2005

Responsible Party:	University of Calgary ( Dr. Charlotte Jones )
Study ID Numbers:	03 71550000144
Study First Received:	January 14, 2008
Last Updated:	September 8, 2008
ClinicalTrials.gov Identifier:	NCT00626041
Health Authority:	Canada: Health Canada

Keywords provided by University of Calgary:

Community pharmacies
Primary care networks
Global risk assessment
Blood pressure screening

Study placed in the following topic categories:

Metabolic Diseases
Hyperlipidemias
Vascular Diseases
Metabolic disorder

Dyslipidemias
Lipid Metabolism Disorders
Hypertension

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009